Key takeaways
- Latisse has a US-approved indication for inadequate eyelashes, increasing their length, thickness and darkness. FDA label.
- Lumigan also contains bimatoprost, but its European indication is reducing raised eye pressure. EMA assessment.
- Bimatoprost can darken the iris; that change may be permanent. Latisse safety information.
- If you already use glaucoma drops, discuss any lash treatment with your eye-care clinician first. FDA interaction warning.
The trial in the cited 2021 FDA label followed 278 adults for four months. At week 16, 78% using Latisse and 18% using the vehicle solution had improved by at least one grade on the Global Eyelash Assessment scale. Investigators also measured lash length, thickness and darkness from digital images. Those were eyelash outcomes; the Lumigan studies measured pressure inside the eye. FDA study, EMA assessment.
Is Latisse just another name for glaucoma drops?
No: Latisse and Lumigan share an ingredient, but their approved purposes and methods of use differ.
| Product example | Overseas approval cited here | Intended purpose |
|---|---|---|
| Latisse | United States | Treat inadequate eyelashes |
| Lumigan | European Union | Reduce raised eye pressure in glaucoma or ocular hypertension |
Latisse is applied to the upper eyelid margin using its supplied applicators. Lumigan is an eye-drop treatment for raised pressure. Neither set of instructions should be borrowed for another product without professional advice. Latisse label, Lumigan assessment.
Remove make-up and clean the face before applying Latisse. The supplied applicator goes along the upper lid margin at the lash base, never along the lower lash line. Blot any excess with a tissue so it does not run onto the cheek. Discard the applicator after treating that eye, then use a fresh one for the other eye. Fingers and other surfaces must not touch the bottle tip or applicator. Application and contamination warnings.
What risks matter when the aim is cosmetic?
Iris darkening may be permanent, and the tissue around the eye can change too.
The Latisse label warns about iris and eyelid pigmentation, eye irritation and unwanted hair growth where the solution repeatedly contacts other skin. The brown pigment can spread outwards from around the pupil and take months or years to become noticeable. It may not reverse. Eyelid-skin darkening may be reversible. FDA warnings.
Bimatoprost product information also describes changes around the eye, including loss of surrounding fat and a deeper upper-eyelid fold. Do not assume that every change is minor or will disappear after stopping. Lumigan product information.
Mention previous eye surgery, inflammation, dry-eye symptoms and contact-lens use before treatment. Latisse contains benzalkonium chloride, which soft lenses can absorb; its label says to remove contact lenses before application and wait 15 minutes before reinserting them. Ask what changes should prompt a review. Pain, worsening vision or significant swelling needs prompt assessment. FDA precautions.
Can you use it alongside glaucoma treatment?
Only with your eye-care clinician’s agreement and appropriate monitoring.
The Latisse label warns that adding it to a prostaglandin analogue used for glaucoma may interfere with the desired reduction in eye pressure. It cites experience with bimatoprost eye drops: using them more often than prescribed can reduce their pressure-lowering effect. Consult the eye-care clinician before adding Latisse and have the pressure response monitored. Interaction information.
Bring the names of all eye drops and lash serums to that consultation. Continue the agreed glaucoma treatment; a lash product cannot replace it.
What should you check before choosing a product?
Check the formulation, supplied applicators and authorised use with the pharmacist.
The cited FDA label describes Latisse in an opaque white bottle with a turquoise cap, supplied with either 70 or 140 sterile disposable applicators. Check the name, ingredient, concentration, packaging and leaflet before comparing prices. A different brand containing bimatoprost may have a different formulation or instructions. Ask the pharmacist to establish its status and proposed use in South Africa. Latisse packaging.
The overseas indications in this article are US eyelash hypotrichosis for Latisse and EU open-angle glaucoma or ocular hypertension in adults for Lumigan. They do not establish approval for every pack advertised online. FDA indication, EMA indication.
Our Vaniqa article explains a medicine that slows unwanted facial hair, while the oral minoxidil guide discusses scalp hair loss. Neither is an interchangeable lash treatment.
Do and don’t
Do:
- Tell your eye-care clinician about every lash serum and eye drop you use.
- Follow the hygiene and applicator instructions supplied with the prescribed product.
Don’t:
- Share bottles or reuse single-use applicators.
- Put a cosmetic lash product into the eye or substitute it for glaucoma treatment.
